Publisher
Paediatrician Publishers LLC
Reference11 articles.
1. Martin R, Beck M, Eng C, et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics. 2008;121(2):e377–e386. https://doi.org/10.1542/peds.2007-135
2. Stapleton M, Kubaski F, Mason RW, et al. Presentation and treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome). Expert Opin Orphan Drugs. 2017;5(4):295–307. https://doi.org/10.1080/21678707.2017.1296761
3. Носко А.С., Зыков В.П., Новикова Е.Б. Алгоритм дифференциальной диагностики неврологических нарушений у пациентов с синдромом Хантера // Поликлиника. — 2022. — № 1. — С. 20–23. [Nosko AS, Zykov VP, Novikova EB. Algorithm of differential diagnosis of neurological disorders in patients with Hunter syndrome. Poliklinika. 2022;(1):20–23. (In Russ).]
4. Holt J, Poe MD, Escolar ML. Early clinical markers of central nervous system involvement in mucopolysaccharidosis type II. J Pediatr. 2011;159(2):320–326.e2. https://doi.org/10.1016/j.jpeds.2011.03.019
5. Shapiro EG, Jones SA, Escolar ML. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations — Neurological signs and symptoms. Mol Genet Metab. 2017;122S:1–7. https://doi.org/10.1016/j.ymgme.2017.08.009